SCHEMBL28467424

SCHEMBL28467424

CC(=O)Nc1cc(C(C)(C)C(F)(F)F)on1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.48
MAPK14 Q16539 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
KDR P35968 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MAPK13 O15264 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
RAF1 P04049 2/20 0.41
BRAF P15056 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078864 0.87 NPC1 (0.48) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL28314210 0.86 EGFR (0.47) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL9416888 0.85 EGFR (0.47) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL20922052 0.84 MAPK14 (0.50) EGFRMAPK14NPC1RAB9AKDR
SCHEMBL21479384 0.83 EGFR (0.44) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL4112548 0.83 EGFR (0.66) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL21479387 0.81 MAPK14 (0.47) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL23975356 0.78 EGFR (0.36) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL9893035 0.77 EGFR (0.51) EGFRMAPK14SMN1; SMN2TDP1NPC1
SCHEMBL1015351 0.77 RAF1 (0.50) EGFRMAPK14NPC1RAB9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365685-B2 Substituted fused aromatic ring derivative, composition and use thereof SHENZHEN TARGETRX, INC. (CN) 2025-07-22 US disclosed
US-20220098204-A1 SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF SHENZHEN TARGETRX, INC. (CN) 2022-03-31 US disclosed
CN-111574521-A Substituted aromatic fused ring derivatives, compositions and uses thereof 深圳市塔吉瑞生物医药有限公司 2020-08-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098204-A1 SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF BRAF, ALK, TYRO3 EGFR 211/4885MAPK14 69/4885SMN1; SMN2 3191/4885
US-12365685-B2 Substituted fused aromatic ring derivative, composition and use thereof BRAF, ALK, TYRO3 EGFR 211/4885MAPK14 69/4885SMN1; SMN2 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.